Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

MiNK Therapeutics, Inc.

INKT · Nasdaq · CIK 0001840229 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

14 Form 4 transaction lines observed in the same window
3 sales · 11 option, withholding, award, gift or other lines

Last qualifying purchase2023-10-16 · AGENUS INC · $472

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesLow
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Ryan BarbaraDirector
○▼○
Holcomb John BradleyDirector
○○
Corvese BrianDirector
○○
Behner PeterDirector
○○
WIINBERG ULFDirector
○○
Buell JenniferChief Executive Officer
○▼
● Purchase▼ Sale○ Other

—

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2023-10-16 · AGENUS INC.

Recent Form 4 activity

0Purchases
9Sales
19Other Form 4 lines
22SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING3 sale line(s) · context only
OTHER11 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
49,583
Previous report
57,136
Avg daily volume
15,898
Days to cover
3.1

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2023-10-16AGENUS INCPurchase (P)Common Stock429USD 1.10USD 472SEC filing ↗
2023-10-13AGENUS INCPurchase (P)Common Stock19,373USD 1.10USD 21,310SEC filing ↗
2023-10-12AGENUS INCPurchase (P)Common Stock3,173USD 1.10USD 3,490SEC filing ↗
2023-10-04AGENUS INCPurchase (P)Common Stock15,001USD 1.09USD 16,351SEC filing ↗
2023-08-29AGENUS INCPurchase (P)Common Stock29,678USD 1.52USD 45,111SEC filing ↗
2023-08-28AGENUS INCPurchase (P)Common Stock12,808USD 1.45USD 18,572SEC filing ↗
2023-08-24AGENUS INCPurchase (P)Common Stock170,244USD 1.54USD 262,176SEC filing ↗
2023-05-11AGENUS INCPurchase (P)Common Stock23,361USD 1.43USD 33,406SEC filing ↗
2023-05-10AGENUS INCPurchase (P)Common Stock22,065USD 1.51USD 33,318SEC filing ↗
2023-05-05AGENUS INCPurchase (P)Common Stock100,200USD 0.95USD 95,250SEC filing ↗
2023-05-04AGENUS INCPurchase (P)Common Stock21,473USD 1.22USD 26,197SEC filing ↗
2023-05-03AGENUS INCPurchase (P)Common Stock128,689USD 1.08USD 138,984SEC filing ↗
2023-05-02ARMEN GARO HPurchase (P)Common Stock100,000USD 0.95USD 95,000SEC filing ↗
2022-07-19WIINBERG ULFPurchase (P)Common Stock16,661USD 1.39USD 23,159SEC filing ↗
2022-07-18WIINBERG ULFPurchase (P)Common Stock3,339USD 1.33USD 4,441SEC filing ↗

Form 4 evidence

28 transaction lines in the latest 365-day window; 121 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-12Buell JenniferSale (S)Common Stock6,938USD 10.56USD 73,265SEC filing ↗
2026-10-11Buell JenniferOption exercise / conversion (M)Common Stock23,191USD —USD —SEC filing ↗
2026-09-01WIINBERG ULFAward / grant (A)Common Stock1,279USD 10.95USD 14,005SEC filing ↗
Show recent Form 4 evidence (25 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-12Buell JenniferSale (S)Common Stock6,938USD 10.56USD 73,265SEC filing ↗
2026-10-11Buell JenniferOption exercise / conversion (M)Common Stock23,191USD —USD —SEC filing ↗
2026-09-01WIINBERG ULFAward / grant (A)Common Stock1,279USD 10.95USD 14,005SEC filing ↗
2026-09-01Ryan BarbaraAward / grant (A)Common Stock1,622USD 10.95USD 17,761SEC filing ↗
2026-09-01Holcomb John BradleyAward / grant (A)Common Stock1,233USD 10.95USD 13,501SEC filing ↗
2026-09-01Corvese BrianAward / grant (A)Common Stock1,633USD 10.95USD 17,881SEC filing ↗
2026-09-01Behner PeterAward / grant (A)Common Stock1,485USD 10.95USD 16,261SEC filing ↗
2026-06-04Ryan BarbaraSale (S)Common Stock1,500USD 12.76USD 19,140SEC filing ↗
2026-06-01WIINBERG ULFAward / grant (A)Common Stock1,131USD 12.38USD 14,002SEC filing ↗
2026-06-01Ryan BarbaraAward / grant (A)Common Stock1,434USD 12.38USD 17,753SEC filing ↗
2026-06-01Holcomb John BradleyAward / grant (A)Common Stock1,091USD 12.38USD 13,507SEC filing ↗
2026-06-01Corvese BrianAward / grant (A)Common Stock1,444USD 12.38USD 17,877SEC filing ↗
2026-06-01Behner PeterAward / grant (A)Common Stock1,313USD 12.38USD 16,255SEC filing ↗
2026-03-10Ryan BarbaraSale (S)Common Stock1,300USD 15.40USD 20,019SEC filing ↗
2026-03-09Ryan BarbaraSale (S)Common Stock200USD 10.17USD 2,034SEC filing ↗
2026-03-02Ryan BarbaraSale (S)Common Stock100USD 10.83USD 1,083SEC filing ↗
2026-02-27Ryan BarbaraSale (S)Common Stock400USD 10.86USD 4,344SEC filing ↗
2026-01-02Buell JenniferTax withholding (F)Common Stock10,024USD 11.12USD 111,467SEC filing ↗
2026-01-02Buell JenniferAward / grant (A)Common Stock31,474USD 11.12USD 349,991SEC filing ↗
2025-12-01WIINBERG ULFAward / grant (A)Common Stock1,263USD 11.09USD 14,007SEC filing ↗
2025-12-01Ryan BarbaraAward / grant (A)Common Stock1,601USD 11.09USD 17,755SEC filing ↗
2025-12-01Kadlec Robert PeterAward / grant (A)Common Stock1,218USD 11.09USD 13,508SEC filing ↗
2025-12-01Holcomb John BradleyAward / grant (A)Common Stock1,128USD 11.09USD 12,510SEC filing ↗
2025-12-01Corvese BrianAward / grant (A)Common Stock1,612USD 11.09USD 17,877SEC filing ↗
2025-12-01Behner PeterAward / grant (A)Common Stock1,466USD 11.09USD 16,258SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerINKT
CIK0001840229
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2836 Biological Products, (No Diagnostic Substances)
ExchangeNasdaq

Data coverage

Local Form 4 history121 transaction lines from 2021-10-19 to 2026-10-12
17 P purchase lines · 10 S sale lines · 94 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.